Prenatal Care & Testing
Cholestasis of Pregnancy: The Itch You Shouldn't Ignore
Intense itching on your palms and soles late in pregnancy isn't just uncomfortable — it may be intrahepatic cholestasis, a liver condition that raises fetal risk when bile acids climb too high. Here's how it's diagnosed, monitored, and managed.
Clinically reviewed · June 2026
Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder specific to pregnancy. It causes intense itching — especially on the palms and soles — from a backup of bile acids in the bloodstream. When total serum bile acids reach 40 µmol/L or higher, fetal risks increase meaningfully; at 100 µmol/L or above, stillbirth risk rises sharply. Prompt diagnosis, ursodeoxycholic acid treatment, serial bile-acid monitoring, and individualized delivery timing are the pillars of management.
What is intrahepatic cholestasis of pregnancy, and why does it happen?
Intrahepatic cholestasis of pregnancy — abbreviated ICP, and sometimes called obstetric cholestasis — is a reversible pregnancy-related liver condition in which the normal flow of bile from the liver into the small intestine slows or stops. As bile backs up, bile acids accumulate in the bloodstream, eventually depositing in skin tissue and producing the condition's most recognizable feature: intense, diffuse itching with no primary skin rash.
ICP is the most common liver disorder specific to pregnancy, affecting 0.3–5.6% of pregnant women depending on ethnicity and geography. Rates are highest in women of South Asian, Scandinavian, and some Indigenous populations, and in Chile, where prevalence historically reaches 5–15% in certain regions. In the United States overall, ICP affects roughly 0.5–1% of pregnancies, though rates vary considerably by population and region.
The precise mechanism is multifactorial. Estrogen and progesterone — both rising steeply in the third trimester — impair the hepatic transport proteins responsible for pumping bile acids out of liver cells and into bile ducts. Genetic susceptibility plays a major role: variants in genes encoding bile-salt export pump (BSEP/ABCB11) and multidrug resistance protein 3 (MDR3/ABCB4) are significantly overrepresented in women with ICP. The genetic component also explains the strong familial clustering — women whose mothers or sisters had ICP are at substantially elevated risk themselves. Environmental factors including low selenium and vitamin D status, and possibly dietary composition, may modulate risk in genetically predisposed women, though these associations are still being characterized in research.
ICP almost always resolves completely within two to six weeks after delivery as bile acid metabolism normalizes. However, the condition carries a 40–70% recurrence rate in future pregnancies, and women with a history of ICP have elevated long-term risk of hepatobiliary disease including gallstones, cholangitis, and, in some studies, non-alcoholic fatty liver disease.
How is cholestasis of pregnancy recognized and diagnosed?
The symptom that should prompt a call to your obstetric provider is intense, persistent itching — particularly on the palms and soles — that begins in the second half of pregnancy, is worst at night, and is not explained by a visible rash. ICP produces no primary skin lesion; any scratch marks, welts, or excoriations visible on the skin are secondary to the itching itself. The itch is characteristically described as burning, crawling, or deep — not superficial — and severe enough in many cases to prevent sleep.
Diagnosis requires blood tests. Your provider will order:
- Total serum bile acids (TSBA) — the primary diagnostic and risk-stratification marker. A result of 10 µmol/L or above (in the context of symptoms and exclusion of other causes) supports ICP.
- Liver function tests — ALT and AST are elevated in most cases of ICP; bilirubin and GGT may also rise in moderate to severe disease.
- An abdominal ultrasound is often obtained to exclude gallstones, viral hepatitis, or other structural explanations.
Because bile acid levels can fluctuate — and because a single normal result does not definitively rule out ICP when symptoms are compelling — your provider may order repeat testing in one to two weeks if your initial results are normal but your symptoms persist. The NCBI StatPearls entry on intrahepatic cholestasis provides a thorough review of the diagnostic criteria and differential diagnosis for clinicians.
If you are experiencing intense palmar or plantar itching after 24 weeks of pregnancy, ask specifically: Can we check my total serum bile acids today? A liver panel alone — without bile acids — may appear relatively normal early in ICP. Bile acids must be specifically ordered.
What are the bile-acid thresholds that define fetal risk?
The fetal risk in ICP is not uniform — it rises in a concentration-dependent fashion with total serum bile acid levels. Current evidence, reflected in 2025 clinical management guidelines published in Maternal-Fetal Medicine, identifies two clinically important thresholds:
- TSBA ≥ 40 µmol/L: The risks of spontaneous preterm birth, prolonged neonatal unit admission, and fetal asphyxia increase significantly above this level. This threshold is the standard trigger for escalation of monitoring and earlier delivery planning in most institutional protocols.
- TSBA ≥ 100 µmol/L (severe ICP): Stillbirth prevalence in singleton pregnancies rises from a population baseline of approximately 0.28% to 3.44% at this level — a more-than-tenfold increase. A 2025 observational cohort study of 198 women with severe ICP found that 7.6% experienced a stillbirth; 86.7% of those losses occurred between 34 and 36 weeks and 6 days of gestation, with important implications for delivery timing decisions in this group.
For women with mild ICP (TSBA below 40 µmol/L), fetal risk appears closer to background population risk, though close monitoring continues throughout. It is important to understand that bile acid levels can rise over time — a level that starts at 25 µmol/L in week 30 may reach 60 µmol/L by week 35 — so serial testing rather than a single measurement guides management.
How is cholestasis of pregnancy treated?
Ursodeoxycholic acid (UDCA) is the established first-line pharmacologic treatment for ICP. It is typically prescribed at 10–15 mg/kg/day in divided doses — a woman weighing 70 kg would take 700–1,050 mg daily, often split into two or three doses. UDCA works by replacing the more toxic endogenous bile acids, reducing their accumulation in liver cells and improving bile flow.
The evidence base for UDCA in ICP is substantial. A definitive individual participant data meta-analysis published in The Lancet Gastroenterology & Hepatology (2021) — drawing on pooled data across multiple randomized controlled trials — found that UDCA significantly reduced total serum bile acids, improved liver enzyme levels, and reduced the risk of preterm birth compared to placebo or other treatments. Critically, however, the same analysis found that UDCA did not independently reduce the risk of stillbirth. This distinction matters clinically: UDCA is an important tool for symptom control and reducing bile acid burden, but it does not eliminate the need for ongoing surveillance and individualized delivery planning based on bile acid levels.
UDCA is generally well tolerated in pregnancy, with a reassuring safety profile based on decades of use. Side effects — primarily loose stools or mild GI upset — are typically manageable at standard doses. Some providers also prescribe antihistamines or topical emollients as adjuncts for itch relief, though these address symptoms only and do not affect the underlying bile acid elevation. Vitamin K supplementation may be recommended if bile acid levels are significantly elevated and fat-soluble vitamin absorption is a concern.
What does ongoing monitoring and delivery planning look like with ICP?
Women diagnosed with ICP are transitioned to closer surveillance. Monitoring typically includes:
- Serial bile acid testing — every one to two weeks once ICP is confirmed, more frequently when levels are approaching or above 40 µmol/L.
- Liver function tests at each surveillance visit to track the trajectory of ALT/AST.
- Fetal monitoring — non-stress tests and/or biophysical profiles are often incorporated into the surveillance plan, particularly for moderate to severe ICP, though standard fetal monitoring does not reliably predict the sudden cardiac events that underlie ICP-related stillbirth. This limitation is important to understand: a reassuring non-stress test on a Tuesday does not mean the risk has resolved.
Delivery timing is individualized. General benchmarks used by many obstetric units in 2026 include:
- Mild ICP (TSBA < 40 µmol/L): Delivery often planned at 37–38 weeks.
- Moderate ICP (TSBA 40–99 µmol/L): Many providers plan delivery at 36–37 weeks, balancing the elevated fetal risk against prematurity risks.
- Severe ICP (TSBA ≥ 100 µmol/L): Earlier delivery — often 34–36 weeks — is considered given the observed stillbirth data in this range.
These benchmarks are informed by the research and consensus documents cited above, including the 2025 MDPI Diagnostics comprehensive review. Your obstetric team will set the specific plan based on your individual bile acid trajectory, your response to UDCA, gestational age, cervical readiness, and any other complicating factors present in your pregnancy.
This article provides general educational information about intrahepatic cholestasis of pregnancy and is not a substitute for individualized medical advice. If you are experiencing symptoms consistent with ICP — intense palms-and-soles itching in the second half of pregnancy — contact your obstetric provider promptly for evaluation.
Frequently asked
What does cholestasis itching feel like, and where does it appear?
The hallmark itch of intrahepatic cholestasis of pregnancy (ICP) is intense and persistent — most women describe it as deep, burning, or crawling rather than a simple surface itch that scratching relieves. It is most concentrated on the palms of the hands and soles of the feet, though it can spread to the arms, legs, and abdomen. Unlike a rash (ICP produces no primary skin lesions), the itch is worst at night and often severe enough to interfere with sleep. It typically begins in the third trimester, most commonly between 28 and 36 weeks. If you are experiencing this pattern, contact your obstetric provider promptly — a blood test for total serum bile acids and liver enzymes can confirm or rule out ICP. This is general information, not a substitute for individual medical advice. See NCBI StatPearls on ICP for the clinical description.
How is intrahepatic cholestasis of pregnancy diagnosed?
Diagnosis requires a blood test measuring total serum bile acids (TSBA) alongside liver function tests (ALT, AST, and sometimes GGT and bilirubin). ICP is confirmed when TSBA is elevated — typically defined as 10 µmol/L or above in most laboratory reference ranges — in the absence of another cause of liver disease. Because TSBA levels can fluctuate, a single normal result does not definitively rule out ICP in a symptomatic patient; repeat testing in one to two weeks is often appropriate if clinical suspicion is high. Liver function tests alone are not sufficient — bile acids must be specifically ordered. Your provider may also request an abdominal ultrasound to exclude gallstones, which can present similarly. According to a 2024 PMC overview of ICP, the condition affects 0.3–5.6% of pregnant women, with significant variation by ethnicity and geography.
At what bile acid level does fetal risk increase significantly?
The fetal risk posed by ICP is closely tied to how high total serum bile acids (TSBA) rise, and the research now identifies two clinically important thresholds. When TSBA reaches 40 µmol/L or above, the risks of spontaneous preterm birth, prolonged neonatal unit admission, and fetal asphyxia increase significantly, according to 2025 clinical management guidelines. At the severe threshold of 100 µmol/L or above, stillbirth prevalence in singleton pregnancies rises from a baseline of 0.28% to 3.44%. A 2025 observational cohort study of 198 women with severe ICP found that 7.6% experienced a stillbirth, with 86.7% of those losses occurring between 34 and 36 weeks and 6 days of gestation — underscoring why serial bile acid monitoring and individualized delivery timing are essential. Always discuss your specific bile acid levels and what they mean for your care with your OB or maternal-fetal medicine specialist.
Does ursodeoxycholic acid (UDCA) treat cholestasis of pregnancy?
Ursodeoxycholic acid (UDCA) is the first-line pharmacologic treatment for ICP and is typically prescribed at 10–15 mg/kg/day in divided doses. It effectively reduces the intensity of pruritus in most women and lowers TSBA levels, improving the quality of life considerably during treatment. A definitive 2021 individual participant data meta-analysis published in The Lancet Gastroenterology & Hepatology found that UDCA reduced the risk of preterm birth in women with ICP, though it has not been shown to independently reduce stillbirth risk. This means UDCA is an important tool for symptom control and may reduce some adverse outcomes, but it does not eliminate the need for bile-acid surveillance and individualized delivery planning. UDCA is generally considered safe in pregnancy, particularly from the second trimester onward. Always take it exactly as prescribed by your provider.
When will my baby be delivered if I have cholestasis of pregnancy?
Delivery timing in ICP is individualized and depends on your total serum bile acid levels, the trajectory of those levels, and your overall clinical picture. Current guidance from 2025 clinical management guidelines supports earlier delivery for women with severely elevated bile acids (100 µmol/L or above) given the elevated stillbirth data. For mild ICP (TSBA below 40 µmol/L), delivery is often planned at 37–38 weeks. For moderate ICP (40–99 µmol/L), many providers plan delivery at 36–37 weeks. These are general benchmarks — your team will set a plan based on your numbers, your UDCA response, and other risk factors. A 2025 cohort study found the majority of stillbirths in severe ICP occurred between 34 and 36 weeks, informing the rationale for earlier delivery in that group.
Will cholestasis of pregnancy recur in a future pregnancy?
Yes — recurrence is common and should be planned for. Women with a history of ICP face a 40–70% recurrence rate in subsequent pregnancies, according to a 2025 MDPI Diagnostics review. This means that in most future pregnancies, ICP will return, often at a similar or slightly earlier gestational age and with comparable bile acid levels — though individual variation exists. Beyond future pregnancies, women who have had ICP also carry an elevated long-term risk of hepatobiliary disease, including gallstones and, in some studies, non-alcoholic fatty liver disease and other biliary conditions. It is worth mentioning your ICP history to your general practitioner or gastroenterologist after delivery so that appropriate follow-up can be arranged. For future pregnancies, bile acid testing should begin earlier than in a typical pregnancy — discuss the surveillance plan with your provider before or at your first prenatal visit.